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Ab s t r Ac t 
Introduction: Increased ovarian production of androgens due to the stimulation of luteinizing hormone (LH) on theca cells can cause 
hyperandrogenism that may present with signs of alopecia in postmenopausal women.
Case description: A 65-year-old postmenopausal woman presented to the gynecology clinic with male-pattern baldness. Serum testosterone 
was high that was suppressed with gonadotropin-releasing hormone analog (GnRH agonist). This confirmed ovarian source of androgens. 
Laparoscopic salpingo-oophorectomy helped reduce androgen levels over a period of an year therefore reversing at least partially the hair loss.
Conclusion: Gonadotropin-releasing hormone analogs can be useful to diagnose the source of increased androgen levels to be of ovarian 
origin. Once confirmed, laparoscopic bilateral salpingo-oophorectomy can reverse hair loss in these cases.
Keywords: Bilateral salpingo-oophorectomy, Gonadotropin analogs, Male-pattern baldness, Ovarian hyperandrogenemia, Postmenopausal 
alopecia.
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In t r o d u c t I o n 
Hyperandrogenism may present with acne, hirsutism, and signs 
of virilization characterized by male-pattern baldness, deepening 
of voice, and clitoromegaly. With reduction of ovarian follicles 
in menopause, there is diminished estrogen and progesterone 
secretion. This increases the impact of androgens on sebaceous 
glands and hair follicles, resulting in the transformation of vellus 
hair follicles to terminal hair follicles.1 The postmenopausal ovary 
remains hormonally active, secreting lower but significant amounts 
of androgens and estrogens.2 The very high gonadotropin levels 
of menopause can maintain androgen production by luteinizing 
hormone (LH) stimulation on theca cells.3,4
cA s e de s c r I p t I o n
Medical History and Clinical Features
A 65-year-old woman presented with progressive male pattern of 
frontal baldness of 2 years duration. She had menopause aged 50 
years and has never used hormone replacement therapy (HRT). She 
had slightly increased facial hair but denied deepening of voice, 
increased muscle mass, or increased libido. She had hypothyroidism 
and hypercholesterolemia controlled on thyroxin and statins. Her 
family history was unremarkable. Her hair appeared to be stubbly 
and brittle. Her body mass index (BMI) was 27 kg/m2.
Investigations
She was initially seen by the endocrinologists. Investigations 
demonstrated an elevated testosterone 5.2 nmol/L (normal 
<3.4 nmol/L), androstenedione 8.9 nmol/L (normal range 
0.9–6.8 nmol/L), sex hormone binding globulin (SHBG) 35 
nmol/L, and free androgen index (FAI) 16.6 nmol/L (normal 
<7 nmol/L). Dehydroepiandrosterone (DHEA) (a marker of adrenal 
androgens) — 3.2 μmol/L was normal. Follicle stimulating hormone 
(FSH) — 52 IU/L, LH — 28 IU/L confirmed menopausal status.
Urinary 24-hour cortisol and steroid profile were normal. 
She suppressed to both low and high doses on dexamethasone 
suppression test. Short synacthen test confirmed normal response. 
Ultrasound examination of the ovaries and the adrenal glands and 
magnetic resonance imaging (MRI) scan of the pituitary gland were 
normal.
Differential Diagnosis
Common differential diagnoses of female alopecia include polycystic 
ovary syndrome (PCOS), obesity-induced hyperandrogenemia, 
androgen-secreting ovarian or adrenal tumors, Cushing’s syndrome, 
congenital adrenal hyperplasia (CAH), and iatrogenic causes, such 
as drugs or surgery.
Treatment
A second free testosterone level was raised at 5.9 nmol/L and 
androstenedione of 9.7 nmol/L. To prove our hypothesis of 
suspected ovarian source of androgens, she was given a trial 
of single 3.75 mg intramuscular dose of leuprorelin acetate, a 
gonadotropin-releasing hormone (GnRH) analog, to suppress 
ovarian function. This significantly reduced her testosterone levels 
to 1.9 nmol/L. The options of long-term treatment with GnRH 
analogs or surgical removal of her ovaries were discussed.
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Operative Findings
She underwent laparoscopic bilateral salpingo-oophorectomy. 
Laparoscopy confirmed bilateral atrophic ovaries macroscopically 
and histology confirmed normal ovarian tissue in keeping with her 
menopausal status.
Outcome and Follow-up
Four months following surgical treatment, testosterone levels 
dropped to 1.1 nmol/L and 1-year follow-up demonstrated cessation 
and partial reversal of her hair loss.
dI s c u s s I o n 
Polycystic ovary syndrome typically presents in early reproductive 
age but do not disappear after menopause and may get worse 
because of imbalance between estrogen and androgens. 
Hyperthecosis is a severe form of PCOS and results from 
overproduction of androgens in the ovarian stromal cells. 
Peripheral estrogens and androgen production are increased and 
these women are often at risk for endometrial hyperplasia and 
carcinoma.5 She had no history of hirsutism, infertility, or irregular 
menses premenopause and her ultrasound scan (USS) showed small 
ovaries ruling out PCOS.
Women with obesity-induced hyperandrogenism have normal 
menarche and irregular menstruation, typically developing 
hirsutism associated with sudden weight gain. This is thought to be 
due to excess aromatase and 5-alpha reductase in adipose tissue 
leading to increased local estrogen and androgens. In this case, 
her BMI was normal.
Congenital adrenal hyperplasia was ruled out with the absence 
of clitoromegaly, presence of normal genital organs along with 
normal short synacthen test.
Ovarian or adrenal tumors usually present with a rapid and 
progressive course. After menopause, ovarian causes of hirsutism 
and virilization are more common compared with adrenal 
disorder.6,7 Ovarian tumors that present with hyperandrogenism 
include Sertoli cell tumors, Leydig cell tumors, and ovarian 
thecomas. These tumors are rare representing only 10% of all 
ovarian tumors. Adrenal androgen-secreting tumors present 
in young children and between 40 years and 50 years. They 
usually secrete DHEA, dehydroepiandrosterone sulfate (DHEAS), 
glucocorticoids, estrogen, and rarely testosterone.8,9
Cushing’s syndrome is caused by adrenal hyperplasia due 
to excess adrenocorticotropic hormone (ACTH). This present 
with tissue bruising, abdominal striae, myopathy, buffalo hump, 
hirsutism, and amenorrhea commonly around 30 to 50 years of 
age. Urinary 24-hour cortisol was normal and a dexamethasone 
suppression test was negative. Dehydroepiandrosterone levels, 
adrenal imaging, and MRI of pituitary gland were normal along with 
the absence of symptoms, ruling out the possibility of Cushing’s 
syndrome and adrenal tumor.
Once ovarian origin of hyperandrogenism was established, 
surgical removal of the ovaries led to reduction of testosterone to 
normal postmenopausal range and therefore symptom control. This 
case illustrates the diagnostic challenges and successful treatment 
of hyperandrogenism in a postmenopausal woman.
co n c lu s I o n 
Alopecia in postmenopausal women could be a very distressing 
problem and in some cases could be because of a serious underlying 
condition. The diagnosis of the etiology could be a challenging 
process. However, in this case, the use of GnRH analogs confirmed 
the ovarian source of increased androgens that was treated 
successfully with laparoscopic bilateral salpingo-oophorectomy. 
Her alopecia was reversed slowly but surely during the 1-year 
follow-up.
le A r n I n g ou tco m e s
• Hyperandrogenemia may lead to male-pattern baldness in 
postmenopausal women that could be a very distressing 
condition and may even signify a potential serious underlying 
pathology.
• Gonadotropin-releasing hormone analogs can help diagnose 
ovarian source of androgens by suppressing the stimulation of 
thecal cells by LH that is usually high in postmenopausal women.
• Once confirmed, laparoscopic removal of the ovaries may 
reverse the alopecia in many cases.
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